VardimanJW,ThieleJ,ArberDA,Brunning., 2009.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,Blood 114 937 -51
MiglinoM,ColomboN,PicaG,GrassoR,ClavioM., 2011.WT1 over expression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia,Leukem Lymph 52 1961 -9
QinY,ZhuH,JiangB,LiJ,LuX, 2009.Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease,Leuk Res 33 384 -90
SakamotoY,MariyaY,SasakiS. WT1, 2009.mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia,Tohoku J Exp Med 219 169 -76
ArefS,El-Sharawy,SabryM,RaoufDA, 2013.Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemia,Indian J Hematol Blood Transfuse 10 1007 -13
2012.´a H, Maalaufov´a-Soukupov´a J. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression,Exp Ther Med 3 129 -33